ACLARIS THERAPEUTICS ANNOUNCES TOP LINE PHASE 2 RESULTS FOR ITS ANTI-TSLP MONOCLONAL ANTIBODY BOSAKITUG (ATI-045) IN ATOPIC DERMATITIS (AD)
ACLARIS THERAPEUTICS ANNOUNCES TOP LINE PHASE 2 RESULTS FOR ITS ANTI-TSLP MONOCLONAL ANTIBODY BOSAKI
ACLARIS THERAPEUTICS ANNOUNCES TOP LINE PHASE 2 RESULTS FOR ITS ANTI-TSLP MONOCLONAL ANTIBODY BOSAKI